Patents Assigned to The Walter & Eliza Hall Institute of Medical Research
-
Publication number: 20240131028Abstract: The present invention relates to a method of chemovaccination against Plasmodium infection comprising administering to a patient an effective amount of a selective inhibitor of plasmepsin X, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 2, 2022Publication date: April 25, 2024Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical ResearchInventors: Justin A. Boddey, David B. Olsen, Ryan Steel, John A. McCauley, Manuel De Lera Ruiz
-
Patent number: 11897864Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.Type: GrantFiled: October 7, 2022Date of Patent: February 13, 2024Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical ResearchInventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
-
Publication number: 20240043404Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.Type: ApplicationFiled: September 6, 2023Publication date: February 8, 2024Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical ResearchInventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
-
Patent number: 11835520Abstract: A system, method, apparatus and diagnostic test for Plasmodium vivax, to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with otherwise undetectable liver-stage hypnozoites. The system, method, apparatus and diagnostic test relate to the identification of hypnozoites (“dormant” liver-stages), or at least of the likelihood of the subject being so infected. Optionally and preferably, the specific timing relates to recent infections, for example within the last 9 months.Type: GrantFiled: December 21, 2017Date of Patent: December 5, 2023Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Ivo Mueller, Takafumi Tsuboi, Michael White, Rhea Longley
-
Publication number: 20230355622Abstract: A method of chemovaccination against Plasmodium infections comprising administering to a patient, an effective amount of a dual inhibitor of plasmepsin IX and X, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 20, 2021Publication date: November 9, 2023Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical ResearchInventors: Justin A. Boddey, David B. Olsen, Ryan Steel
-
Patent number: 11779639Abstract: The present disclosure provides mutant parasites, in particular protozoan parasites comprising a mutation of the trehalose-6-phosphate synthase/6-phosphate phosphatase (TPS/TPP)-like gene of Toxoplasma gondii (herein referred to as ‘Toxoplasma’) or a homologue thereof as well as vaccines comprising same.Type: GrantFiled: May 10, 2019Date of Patent: October 10, 2023Assignees: The Walter and Eliza Hall Institute of Medical Research, The University of MelbourneInventors: Chris Tonkin, Alessandro Uboldi, Malcolm McConville, Martin Blume
-
Patent number: 11766435Abstract: The present invention provides methods of treating malaria comprising administration of an N3-substituted iminopyrimidinone of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables R1, R2, R3, R4, R5, A, B, L, m, and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: GrantFiled: February 13, 2017Date of Patent: September 26, 2023Assignees: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs
-
Publication number: 20230201257Abstract: Provided herein is a family of programmable de novo designed transmembranal protein domain polypeptides, and uses thereof in the production of engineered chimeric antigen receptor T (CAR T) cells, which are used, for example, to fight cancer.Type: ApplicationFiled: November 14, 2022Publication date: June 29, 2023Applicants: Yeda Research and Development Co. Ltd., The Walter and Eliza Hall Institute of Medical ResearchInventors: Sarel FLEISHMAN, Assaf ELAZAR, Jonathan Y. WEINSTEIN, Melissa J. CALL, Matthew E. CALL, Nicholas J. CHANDLER
-
Publication number: 20230143532Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.Type: ApplicationFiled: October 7, 2022Publication date: May 11, 2023Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical ResearchInventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
-
Publication number: 20230139282Abstract: Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: February 2, 2021Publication date: May 4, 2023Applicants: Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research, MSD R&D (China) Co., Ltd.Inventors: Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, John A. McCauley, David B. Olsen, Brad Sleebs, Tony Triglia, Dongmei Zhan, Lianyun Zhao
-
Publication number: 20230013692Abstract: The present invention provides methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for the possible inhibition of plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: November 16, 2020Publication date: January 19, 2023Applicants: Merck Sharp & Dohme LLC, MSD R&D (China) Co. Ltd., The Walter and Eliza Hall Institute of Medical ResearchInventors: John A. McCauley, Manuel de Lera Ruiz, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Dongmei Zhan, Lianyun Zhao
-
Publication number: 20220331321Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: July 21, 2020Publication date: October 20, 2022Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical Research, MSD R & D (China) Co. LTD.Inventors: John A. McCauley, Alan F. Cowman, Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Jennifer K. Thompson, Tony Triglia, Dongmei Zhan, Cailing Zhang, Lianyun Zhao
-
Publication number: 20220315555Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.Type: ApplicationFiled: November 3, 2021Publication date: October 6, 2022Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical ResearchInventors: Milan BRUNCKO, Hong DING, George A. DOHERTY, Steven W. ELMORE, Lisa A. HASVOLD, Laura HEXAMER, Aaron R. KUNZER, Xiaohong SONG, Andrew J. SOUERS, Gerard M. SULLIVAN, Zhi-Fu TAO, Gary T. WANG, Le WANG, Xilu WANG, Michael D. WENDT, Robert MANTEI, Todd M. HANSEN
-
Publication number: 20220267447Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells.Type: ApplicationFiled: April 13, 2022Publication date: August 25, 2022Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Nicholas D. Huntington, Sandra E. Nicholson
-
Patent number: 11326134Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.Type: GrantFiled: November 11, 2019Date of Patent: May 10, 2022Assignees: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, GRAINS RESEARCH AND DEVELOPMENT CORPORATION, MELBOURNE HEALTHInventors: Gregory John Tanner, Crispin Alexander Howitt
-
Patent number: 11279760Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.Type: GrantFiled: July 19, 2021Date of Patent: March 22, 2022Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Nicholas D. Huntington, Sandra E. Nicholson
-
Patent number: 11248034Abstract: The present invention relates to insulin analogs, particularly insulin analogs having shortened B chains. The present invention also relates to the crystal structure of insulin from the venom of cone snails and to methods of using the crystal and related structural information to screen for and design insulin analogs that interact with or modulate the insulin receptor. The present invention also relates to therapeutic and prophylactic methods using insulin analogs.Type: GrantFiled: July 21, 2017Date of Patent: February 15, 2022Assignees: University of Utah Research Foundation, The Walter and Eliza Hall Institute of Medical ResearchInventors: John Gerbrandt Tasman Menting, Brian Smith, Danny Hung-Chieh Chou, Helena Safavi-Hemami, Michael Colin Lawrence, Baldomero M. Olivera
-
Publication number: 20220025048Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells.Type: ApplicationFiled: July 19, 2021Publication date: January 27, 2022Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Nicholas D. Huntington, Sandra E. Nicholson
-
Publication number: 20220025328Abstract: The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells.Type: ApplicationFiled: August 4, 2021Publication date: January 27, 2022Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Nicholas D. Huntington, Sandra E. Nicholson
-
Publication number: 20210379020Abstract: The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: ApplicationFiled: August 11, 2021Publication date: December 9, 2021Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical ResearchInventors: Tanweer A. Khan, Jared N. Cumming, David B. Olsen, Justin A. Boddey, Alan F. Cowman, Brad E. Sleebs